HeraMED (ASX:HMD) ROE % Adjusted to Book Value: -13.82% (As of Dec. 2025)


What is HeraMED ROE % Adjusted to Book Value?

HeraMED ASX:HMD -2.63% ROE % Adjusted to Book Value is -13.82% as of Dec. 2025. The stock has 2 warning signs investors should review.

HeraMED's ROE % for the quarter that ended in Dec. 2025 was -497.68%. HeraMED's PB Ratio for the quarter that ended in Dec. 2025 was 36.00. HeraMED's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -13.82%.

HeraMED ROE % Adjusted to Book Value Related Terms

HeraMED ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for HeraMED's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeraMED ROE % Adjusted to Book Value Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 -49.15 -23.02 -47.64 -6.20

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.73 -60.15 -34.64 -38.52 -13.82

ASX:HMD vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, HeraMED's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HeraMED ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where HeraMED's ROE % Adjusted to Book Value falls into.


HeraMED ROE % Adjusted to Book Value Calculation

HeraMED's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-223.23% / 36.00
=-6.20%

HeraMED's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-497.68% / 36.00
=-13.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -13.82% mean?
HeraMED (ASX:HMD) has a ROE % Adjusted to Book Value of -13.82% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on HeraMED and its competitors.
Is HeraMED's ROE % Adjusted to Book Value too high?
HeraMED's current ROE % Adjusted to Book Value is -13.82%.
How does HeraMED's ROE % Adjusted to Book Value compare to ABT and SYK?
HeraMED's ROE % Adjusted to Book Value of -13.82% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on HeraMED and its competitors. HeraMED's current ROE % Adjusted to Book Value is -13.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 85% above its estimated fair value. The current ROE % Adjusted to Book Value is -13.82%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current ROE % Adjusted to Book Value is -13.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeraMED Business Description

Other Exchanges 1I4:Germany
Address 117 Camberwell Road, Level 1 - Suite 1, Hawthorn East, Melbourne, VIC, AUS, 3123
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.